Cargando…

Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells

BACKGROUND: Despite the progress made in the clinical management of metastatic melanoma, a patient’s response to treatment cannot be fully predicted, and intrinsic or acquired resistance that is developed in most melanoma patients warrants further research efforts. In addition to genetic factors, mi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Osrodek, Marta, Rozanski, Michal, Czyz, Malgorzata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501594/ https://www.ncbi.nlm.nih.gov/pubmed/32982400 http://dx.doi.org/10.2147/CMAR.S263767

Ejemplares similares

Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program
por: Czyz, Malgorzata, et al.
Publicado: (2019)

Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of (V600E)BRAF melanoma cells and their response to vemurafenib and trametinib in vitro
por: Zalesna, Izabela, et al.
Publicado: (2017)

TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve, vemurafenib- and trametinib-resistant BRAF(V600E) melanoma cells
por: Hartman, Mariusz L., et al.
Publicado: (2019)

Physiologically Relevant Oxygen Concentration (6% O(2)) as an Important Component of the Microenvironment Impacting Melanoma Phenotype and Melanoma Response to Targeted Therapeutics In Vitro
por: Osrodek, Marta, et al.
Publicado: (2019)

Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma
por: Mistry, Hitesh B., et al.
Publicado: (2017)

Pro-Apoptotic Activity of MCL-1 Inhibitor in Trametinib-Resistant Melanoma Cells Depends on Their Phenotypes and Is Modulated by Reversible Alterations Induced by Trametinib Withdrawal
por: Hartman, Mariusz L., et al.
Publicado: (2023)

Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
por: Joshi, Monika, et al.
Publicado: (2015)

Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients
por: Daud, Adil, et al.
Publicado: (2017)

17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF(V600E) inhibitors in melanoma cells of different genetic subtypes
por: Mielczarek-Lewandowska, Aleksandra, et al.
Publicado: (2019)

Targeting Genome Stability in Melanoma—A New Approach to an Old Field
por: Osrodek, Marta, et al.
Publicado: (2021)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Sorafenib sensitizes melanoma cells to vemurafenib through ferroptosis
por: Tang, Fengjie, et al.
Publicado: (2020)

Trametinib-Resistant Melanoma Cells Displaying MITF(high)/NGFR(low)/IL-8(low) Phenotype Are Highly Responsive to Alternating Periods of Drug Withdrawal and Drug Rechallenge
por: Koziej, Paulina, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China
por: Gao, Tianfu, et al.
Publicado: (2021)

Metastatic melanoma and vemurafenib: novel approaches
por: De Mello, Ramon Andrade
Publicado: (2012)

A STATement on Vemurafenib-Resistant Melanoma
por: Hartsough, Edward J., et al.
Publicado: (2013)

Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance
por: Peng, Jianyu, et al.
Publicado: (2023)

Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model
por: Kawaguchi, Kei, et al.
Publicado: (2016)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma
por: Amaro, Adriana Agnese, et al.
Publicado: (2023)

Vemurafenib resistance reprograms melanoma cells towards glutamine dependence
por: Hernandez-Davies, Jenny E, et al.
Publicado: (2015)

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells()
por: Mologni, Luca, et al.
Publicado: (2018)

Trametinib: A Targeted Therapy in Metastatic Melanoma
por: Hoffner, Brianna, et al.
Publicado: (2018)

RNA sequencing data of Vemurafenib-resistant melanoma cells and parental cells
por: Zhao, Kun, et al.
Publicado: (2020)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
por: Sponghini, Andrea P, et al.
Publicado: (2015)

Primary Melanoma of the Lung Treated with Surgery, Dabrafenib and Trametinib
por: Landgraf, Layla G., et al.
Publicado: (2020)

Trametinib: a MEK inhibitor for management of metastatic melanoma
por: Lugowska, Iwona, et al.
Publicado: (2015)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma
por: Cui, Hongmei, et al.
Publicado: (2021)

Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma
por: Hagen, Brenda, et al.
Publicado: (2014)

Telmisartan induces melanoma cell apoptosis and synergizes with vemurafenib in vitro by altering cell bioenergetics
por: Grahovac, Jelena, et al.
Publicado: (2019)

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
por: Homet Moreno, Blanca, et al.
Publicado: (2015)

Dermoscopic assessment of skin toxicities in patients with melanoma during treatment with vemurafenib
por: Rajczykowski, Marcin, et al.
Publicado: (2018)

Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
por: Atzori, Maria Grazia, et al.
Publicado: (2019)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals
por: Tabolacci, Claudio, et al.
Publicado: (2021)

Analysis of Alternative mRNA Splicing in Vemurafenib-Resistant Melanoma Cells
por: Bokharaie, Honey, et al.
Publicado: (2022)

Identification of Dihydrolipoamide Dehydrogenase as Potential Target of Vemurafenib-Resistant Melanoma Cells
por: Tabolacci, Claudio, et al.
Publicado: (2022)

3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells
por: Vital, Patrik da Silva, et al.
Publicado: (2022)

A New Role of Vemurafenib as a Neoadjuvant Treatment of Axillary and Brain Melanoma Metastases
por: Melnik, Idit, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_292t4qb6hujhekjl1dnmujp6n5